Follow us on
Search News Archives
Conferences | Events
Lab Bulletin Media Partners

Circulating Tumor DNA Reference Standards

publication date: Oct 12, 2018
 | 
author/source: AMS Biotechnology (Europe) Ltd

test tube


AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research.

A critical goal in cancer disease management is early detection. When detected early, cancer progression can be arrested using techniques such as targeted therapy, chemotherapy and surgery thereby increasing the chances of survival and a higher quality of life. Liquid biopsy offers the promise of providing a quick, non-invasive and cost-effective alternative to surgical biopsies, allowing tumor analysis through a simple blood sample. Traces of the ctDNA in the blood offer the potential of not only earlier cancer detection, but may also guide therapy selection, enabling routine monitoring of cancer to assess minimal residual disease, and resistance monitoring during treatment.

Advances in Next-Generation Sequencing (NGS) and digital PCR (dPCR) are accelerating the development of quantitative assays that can the detect low amounts of mutant DNA present in blood samples, often down to 1 in 1000 mutant alleles (0.1%) or lower. These developments have enabled non-invasive cancer profiling of associated somatic variants from ctDNA.

AMSBIO now offers ctDNA Reference Standards highly characterized, quantitative multiplex quality controls to support the development of assays. These standards are engineered to mimic the fragmentation profile of nucleosomal ctDNA (~166 bp) observed in patient samples across are range of allele frequencies. Pre-validated by digital PCR, cancer-associated mutations are included across EGFR, PIK3CA, NRAS and KRAS samples.

Based on CRISPR/Cas9 isogenic cell lines, AMSBIO Patient-Like circulating ctDNA is available as purified DNA or in a synthetic plasma. These reference standards can be directly incorporated into assay optimization, as an essential control for evaluating of limits of detection and specificity.


more from amsbio



If you have not logged into the website then please enter your details below.



 

Popular this month


 

Win an INTEGRA VOYAGER adjustable tip spacing pipette


Thermo Fisher Scientific Announces Collaboration to Simplify Analysis of Complex Therapeutic Proteins


World’s first high throughput microplate reader for circular dichroism


Eppendorf Presents First Internally Developed CO2 Incubator


Thinking about buying a LIMS? Pick wisely!


Lab Innovations 2018 confirmed as a major hit with visitors, exhibitors and speakers


Take your microwell plate pipetting to the next level!


ZEISS and arivis AG Intensify Strategic Partnership


New RenataDX Screening System Delivers Fast, Accurate Results for Clinical Scientists


Stunning Weevil Eye Wins Forty-Fourth Annual Nikon Small World Competition

 

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd